rec 0438

REC 0438 is a peptide-based small molecule drug developed by Recordati for the treatment of overactive bladder, particularly in patients with neurogenic detrusor overactivity due to spinal cord injury. It is administered via intravesical instillation and has reached Phase 2 clinical development. The precise mechanism of action has not been fully defined in public sources; however, it is described as a NOP (nociceptin/orphanin FQ peptide) receptor ligand in pharmacological literature. This suggests that its therapeutic effect may be mediated through modulation of the NOP receptor system, which plays a role in regulating bladder function and other biological processes[1][2].